New diabetes drug QLG1091 takes on rybelsus in Head-to-Head trial
NCT ID NCT07487103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new oral diabetes medication, QLG1091, to the existing drug Rybelsus, both taken alongside metformin. About 478 adults with type 2 diabetes will take one of the two pills daily for 26 weeks. The goal is to see if QLG1091 controls blood sugar (HbA1c) as well as Rybelsus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLG1091 (a new oral diabetes drug)
- What this could lead to
- If successful, QLG1091 could offer a new, effective oral option for managing type 2 diabetes alongside metformin.
- What could go wrong
- This is an early-stage comparison study, not a cure. The new drug may not be as effective or safe as Rybelsus, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?